EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Aptamer Group's enterprise value is £3.04 Mil.
Aptamer Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was £1.04 Mil. Therefore, Aptamer Group's EV-to-Revenue for today is 2.94.
The historical rank and industry rank for Aptamer Group's EV-to-Revenue or its related term are showing as below:
LSE:APTA'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.03 Med: 4.98 Max: 119.18
Current: 2.93
During the past 4 years, the highest EV-to-Revenue of Aptamer Group was 119.18. The lowest was 0.03. And the median was 4.98.
LSE:APTA's EV-to-Revenue is ranked better than 73.44% of 1039
companies
in the Biotechnology industry
Industry Median: 8.18
vs LSE:APTA: 2.93
As of today (2024-05-26), Aptamer Group's stock price is £0.008.
Aptamer Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was £0.01. Therefore, Aptamer Group's PS Ratio for today is 0.67.
Aptamer Group EV-to-Revenue Historical Data
The historical data trend for Aptamer Group's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aptamer Group's EV-to-Revenue
For the Biotechnology subindustry, Aptamer Group's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aptamer Group's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aptamer Group's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Aptamer Group's EV-to-Revenue falls into.
Aptamer Group's current Enterprise Value is £3.04 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aptamer Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was £1.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aptamer Group (LSE:APTA) EV-to-Revenue Explanation
Aptamer Group's share price for today is £0.008.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was £0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aptamer Group EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Aptamer Group's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Aptamer Group PLC provides Optimer binders for use in research, diagnostics and therapeutics. It strives to deliver transformational solutions that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer technology. Its businesses: Aptamer Solutions for custom Optimer development, Aptamer Diagnostics for in-house and collaborative Optimer-based diagnostic development and Aptamer Therapeutics for the development of Optimer-based therapeutics.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:APTA has been successfully added to your